No supplier or customer ties in SRZN's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Nothing on the wire mentions SRZN yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How SRZN has moved on past release days vs its typical ±3.9% day, and how often it closed up. Computed from daily closes — not a forecast.